Acorai

Company Description

Acorai is a Swedish medical device company with a mission to build state-of-the-art and cost-efficient non-invasive technologies for improved heart failure management. The company has raised $13M from investors, been awarded $4M in grants, was FDA Breakthrough Device Designated in 2023 and is expected to reach the US market in 2026. Acorai has developed the SAVE Sensor System: a multi-sensor platform for non-invasive pulmonary artery and cardiac pressure sensing, which has been clinically tested in over 1800 patients and 15 hospitals across 6 countries.